Univariate and multivariate correlations with the best eGFR obtained during follow-up
| Variable . | Univariate (mL/min/1.73 m2) . | P (trend test) . | Multivariate standardized β . | P . |
|---|---|---|---|---|
| Age, y | ≤60: 56 ± 37 | <.001 | −0.274 | .002 |
| 61-70: 38 ± 29 | ||||
| >70: 38 ± 23 | ||||
| LCCN at myeloma relapse | No: 44 ± 31 | .002 | — | |
| Yes: 23 ± 15 | ||||
| Presenting eGFR, mL/min/1.73 m2 | ≥30: 65 ± 36 | <.001 | — | |
| 15-29: 60 ± 30 | ||||
| <15: 36 ± 26 | ||||
| Baseline serum FLC level, mg/L | ≤3500: 48 ± 39 | .03 | — | |
| 3501-7000: 41 ± 34 | ||||
| >7000: 35 ± 28 | ||||
| β2-microglobulin, mg/L | <10: 57 ± 36 | <.001 | −0.365 | <.001 |
| 10-20: 50 ± 25 | ||||
| >20: 25 ± 21 | ||||
| 60% reduction in serum FLC level after the first cycle | Present: 50 ± 29 | .001 | * | |
| Absent: 31 ± 31 | ||||
| Best hematologic response | VGPR or better: 49 ± 30 | <.001 | 0.21 (VGPR or better vs PR or worse) | .01 |
| PR: 38 ± 30 | ||||
| Stable disease or worse: 22 ± 20 | ||||
| Best serum FLC level, mg/L | ≤25: 58 ± 31 | <.001 | * | |
| 26-500: 42 ± 30 | ||||
| >500: 25 ± 19 | ||||
| Interstitial fibrosis or tubular atrophy | 0 to ≥1: 48 ± 32 | .01 | −0.20 | .02 |
| 2 to ≥3: 36 ± 26 | ||||
| THP extravasation | Present: 57 ± 35 | <.001 | — | |
| Absent: 36 ± 26 | ||||
| Giant cell reaction around casts | Present: 38 ± 28 | .02 | — | |
| Absent:50 ± 33 | ||||
| Cortex: mean no. of casts/mm2 | ≤2: 52 ± 33 | <.001 | −0.23 | .008 |
| 2-5: 42 ± 30 | ||||
| >5: 32 ± 24 | ||||
| Medulla: mean no. of casts/mm2 | ≤1.5: 56 ± 33 | <.001 | † | |
| 1.5-3.0: 41 ± 27 | ||||
| >3.0: 33 ± 26 | ||||
| Glomerular amyloidosis or LCDD | Present: 21 ± 16 | <.001 | — | |
| Absent: 44 ± 31 |
| Variable . | Univariate (mL/min/1.73 m2) . | P (trend test) . | Multivariate standardized β . | P . |
|---|---|---|---|---|
| Age, y | ≤60: 56 ± 37 | <.001 | −0.274 | .002 |
| 61-70: 38 ± 29 | ||||
| >70: 38 ± 23 | ||||
| LCCN at myeloma relapse | No: 44 ± 31 | .002 | — | |
| Yes: 23 ± 15 | ||||
| Presenting eGFR, mL/min/1.73 m2 | ≥30: 65 ± 36 | <.001 | — | |
| 15-29: 60 ± 30 | ||||
| <15: 36 ± 26 | ||||
| Baseline serum FLC level, mg/L | ≤3500: 48 ± 39 | .03 | — | |
| 3501-7000: 41 ± 34 | ||||
| >7000: 35 ± 28 | ||||
| β2-microglobulin, mg/L | <10: 57 ± 36 | <.001 | −0.365 | <.001 |
| 10-20: 50 ± 25 | ||||
| >20: 25 ± 21 | ||||
| 60% reduction in serum FLC level after the first cycle | Present: 50 ± 29 | .001 | * | |
| Absent: 31 ± 31 | ||||
| Best hematologic response | VGPR or better: 49 ± 30 | <.001 | 0.21 (VGPR or better vs PR or worse) | .01 |
| PR: 38 ± 30 | ||||
| Stable disease or worse: 22 ± 20 | ||||
| Best serum FLC level, mg/L | ≤25: 58 ± 31 | <.001 | * | |
| 26-500: 42 ± 30 | ||||
| >500: 25 ± 19 | ||||
| Interstitial fibrosis or tubular atrophy | 0 to ≥1: 48 ± 32 | .01 | −0.20 | .02 |
| 2 to ≥3: 36 ± 26 | ||||
| THP extravasation | Present: 57 ± 35 | <.001 | — | |
| Absent: 36 ± 26 | ||||
| Giant cell reaction around casts | Present: 38 ± 28 | .02 | — | |
| Absent:50 ± 33 | ||||
| Cortex: mean no. of casts/mm2 | ≤2: 52 ± 33 | <.001 | −0.23 | .008 |
| 2-5: 42 ± 30 | ||||
| >5: 32 ± 24 | ||||
| Medulla: mean no. of casts/mm2 | ≤1.5: 56 ± 33 | <.001 | † | |
| 1.5-3.0: 41 ± 27 | ||||
| >3.0: 33 ± 26 | ||||
| Glomerular amyloidosis or LCDD | Present: 21 ± 16 | <.001 | — | |
| Absent: 44 ± 31 |
Patients with a minimum 2 months’ follow-up and one cycle of treatment were included (n = 154). We included all the variables associated by univariate analysis in the multivariate model except for “60% reduction in serum FLC level after the first cycle” and “best FLC” because they are closely interrelated by definition to “best hematologic response” (*). We also excluded the “mean number of medullary casts” since the medulla was absent in 40% (†).
NR, no response; PR, partial response.